JOP20220296A1 - مركبات غير متجانسة الحلقات كمستقبل حاث يتم التعبير عنه على مواد مساعدة للخلايا النقيية 2 وطرق استخدامها - Google Patents
مركبات غير متجانسة الحلقات كمستقبل حاث يتم التعبير عنه على مواد مساعدة للخلايا النقيية 2 وطرق استخدامهاInfo
- Publication number
- JOP20220296A1 JOP20220296A1 JOJO/P/2022/0296A JOP20220296A JOP20220296A1 JO P20220296 A1 JOP20220296 A1 JO P20220296A1 JO P20220296 A JOP20220296 A JO P20220296A JO P20220296 A1 JOP20220296 A1 JO P20220296A1
- Authority
- JO
- Jordan
- Prior art keywords
- expressed
- methods
- heterocyclic compounds
- compounds
- myeloid cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019772P | 2020-05-04 | 2020-05-04 | |
| PCT/US2021/070507 WO2021226629A1 (en) | 2020-05-04 | 2021-05-04 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220296A1 true JOP20220296A1 (ar) | 2022-11-02 |
Family
ID=78468522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2022/0296A JOP20220296A1 (ar) | 2020-05-04 | 2022-11-02 | مركبات غير متجانسة الحلقات كمستقبل حاث يتم التعبير عنه على مواد مساعدة للخلايا النقيية 2 وطرق استخدامها |
Country Status (21)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| CN116322696A (zh) | 2020-05-04 | 2023-06-23 | 安进公司 | 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法 |
| US20230082623A1 (en) * | 2020-12-04 | 2023-03-16 | Vigil Neuroscience, Inc. | Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists |
| TW202309029A (zh) * | 2021-05-04 | 2023-03-01 | 美商維佳神經科學有限公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| EP4430029A4 (en) * | 2021-11-09 | 2025-09-10 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE |
| TW202325290A (zh) * | 2021-11-09 | 2023-07-01 | 美商維佳神經科學有限公司 | 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法 |
| US20260152484A1 (en) * | 2021-11-09 | 2026-06-04 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists |
| EP4499693A1 (en) * | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2024233848A1 (en) * | 2023-05-10 | 2024-11-14 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| CN121443608A (zh) * | 2023-07-17 | 2026-01-30 | 穆纳治疗有限公司 | Trem2调节剂 |
| WO2025128848A1 (en) * | 2023-12-12 | 2025-06-19 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| AU2025206254A1 (en) | 2024-01-04 | 2026-06-11 | Muna Therapeutics Aps | Trem2 modulators |
| IL328677A (en) | 2024-01-04 | 2026-07-01 | Muna Therapeutics Aps | 2-Azatidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-8,7-dihydropyrimido[4,5-D]pyrimidine derivatives as TREM2 modulators for the treatment of neurodegenerative diseases |
| WO2025157993A1 (en) * | 2024-01-24 | 2025-07-31 | Muna Therapeutics Aps | Trem2 modulators |
| WO2026024121A1 (en) * | 2024-07-25 | 2026-01-29 | Yuhan Corporation | Bicyclic fused-ring derivative or salt thereof and pharmaceutical composition including the same |
| WO2026077861A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
| WO2026077862A1 (en) * | 2024-10-07 | 2026-04-16 | F. Hoffmann-La Roche Ag | Trem2 agonists |
| WO2026099455A1 (en) * | 2024-11-08 | 2026-05-15 | Muna Therapeutics Aps | Dihydropyrrolopyrimidinone compounds as trem2 modulators |
| WO2026115009A1 (en) * | 2024-11-29 | 2026-06-04 | F. Hoffmann-La Roche Ag | Trem2 agonists |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US2963481A (en) | 1959-11-27 | 1960-12-06 | Smith Kline French Lab | 6-pteridinecarboxylic acid esters |
| US3712892A (en) | 1969-08-02 | 1973-01-23 | Sumitomo Chemical Co | Quinazolinone derivatives |
| JPH05170744A (ja) * | 1991-12-25 | 1993-07-09 | Toray Dow Corning Silicone Co Ltd | 含窒素芳香族複素環式化合物のアルキル化方法 |
| IL112235A (en) | 1994-01-03 | 2000-06-29 | Acea Pharm Inc | 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them |
| SI1028950T1 (en) | 1997-10-28 | 2003-08-31 | Warner-Lambert Company Llc | 7-substituted quinazolin-2,4-diones useful as antibacterial agents |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| JP2004521892A (ja) | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 |
| JP2003005355A (ja) | 2001-06-20 | 2003-01-08 | Fuji Photo Film Co Ltd | 電子線又はｘ線用ネガ型レジスト組成物 |
| ES2440217T3 (es) | 2002-10-04 | 2014-01-28 | Prana Biotechnology Limited | Compuestos neurológicamente activos |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| PT1673092E (pt) | 2003-10-17 | 2007-11-23 | 4 Aza Ip Nv | ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia'' |
| CA2543710A1 (en) | 2003-11-03 | 2005-05-12 | Warner-Lambert Company Llc | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| BRPI0507629A (pt) | 2004-02-13 | 2007-07-03 | Banyu Pharma Co Ltd | composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável |
| WO2005087742A1 (en) * | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| DK1737831T3 (da) | 2004-04-02 | 2013-08-19 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| MX2007010401A (es) * | 2005-02-25 | 2008-02-19 | Kudos Pharm Ltd | Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor. |
| WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| KR100659088B1 (ko) | 2005-07-15 | 2006-12-21 | 삼성에스디아이 주식회사 | 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자 |
| WO2007038331A2 (en) | 2005-09-23 | 2007-04-05 | Smithkline Beecham Corporation | Novel chemical compounds |
| EP1996191A4 (en) | 2006-03-02 | 2010-05-19 | Glaxosmithkline Llc | THIAZOLONE AS A PI3 KINASE INHIBITOR |
| US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| US20090318456A1 (en) | 2006-07-06 | 2009-12-24 | Gilead Sciences, Inc. | Substituted pteridines for the treatment and prevention of viral infections |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| JP5227321B2 (ja) | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
| EP2142509B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| BRPI0818426A2 (pt) | 2007-10-15 | 2017-06-13 | Astrazeneca Ab | produto de combinação, uso de um produto de combinação, e, método para tratar câncer |
| US20110098267A1 (en) | 2008-02-07 | 2011-04-28 | Synta Pharmaceuticals Corporation | Topical formulations for the treatment of psoriasis |
| US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
| WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| ES2617873T3 (es) | 2008-10-10 | 2017-06-20 | Vm Discovery, Inc. | Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades |
| JP2012520887A (ja) | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| CN102574847A (zh) | 2009-07-30 | 2012-07-11 | Irm责任有限公司 | 作为syk激酶抑制剂的化合物和组合物 |
| WO2011014039A1 (en) | 2009-07-31 | 2011-02-03 | Rohm And Haas Electronic Materials Korea Ltd. | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
| US20110124597A1 (en) | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
| JP5993742B2 (ja) | 2009-10-29 | 2016-09-14 | ジェノスコ | キナーゼ阻害剤 |
| EP2547664B1 (de) * | 2010-03-16 | 2016-05-04 | Merck Patent GmbH | Morpholinylchinazoline |
| WO2011156889A1 (en) | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| US10260097B2 (en) * | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
| KR101497124B1 (ko) | 2011-11-28 | 2015-03-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치 |
| EA039373B1 (ru) | 2012-02-08 | 2022-01-19 | Янссен Сайенсиз Айрлэнд Юси | Производные пиперидино-пиримидина для лечения вирусных инфекций |
| CN103374021B (zh) | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
| WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| EP3027616B1 (en) | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| US9815797B2 (en) | 2013-12-09 | 2017-11-14 | Ucb Biopharma Sprl | Fused bicyclic heteroaromatic derivatives as modulators of TNF activity |
| KR20150080966A (ko) | 2014-01-02 | 2015-07-13 | 최돈수 | 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료 |
| KR20160060572A (ko) | 2014-11-19 | 2016-05-30 | 주식회사 엠비케이 | 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기 |
| PE20180316A1 (es) | 2015-04-15 | 2018-02-09 | Hoffmann La Roche | Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda |
| US10403826B2 (en) | 2015-05-07 | 2019-09-03 | Universal Display Corporation | Organic electroluminescent materials and devices |
| EP3335254B1 (de) | 2015-08-11 | 2020-04-08 | Merck Patent GmbH | Materialien für organische elektrolumineszenzvorrichtungen |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10573692B2 (en) | 2016-04-06 | 2020-02-25 | Samsung Display Co., Ltd. | Organic light-emitting device having a sealing thin film encapsulation portion |
| IL307931A (en) | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| CA3039124A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2018066812A1 (en) | 2016-10-05 | 2018-04-12 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent compound and organic electroluminescent device comprising the same |
| CN109790183A (zh) | 2016-12-13 | 2019-05-21 | 广州华睿光电材料有限公司 | 金属有机配合物及其应用、混合物、有机电子器件 |
| GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| TW201843143A (zh) | 2017-03-13 | 2018-12-16 | 德商麥克專利有限公司 | 含有芳基胺結構之化合物 |
| WO2018169352A1 (en) | 2017-03-16 | 2018-09-20 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent device |
| KR102335935B1 (ko) | 2017-03-22 | 2021-12-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| AU2018243749A1 (en) | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| KR102389204B1 (ko) | 2017-04-18 | 2022-04-21 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| WO2018204765A1 (en) | 2017-05-05 | 2018-11-08 | Pairnomix, Llc | Methods of treating epilepsy and kcnq2 related conditions |
| WO2018227228A1 (en) | 2017-06-13 | 2018-12-20 | Commonwealth Scientific And Industrial Research Organisation | Antiviral drugs |
| US20200275661A1 (en) | 2017-09-26 | 2020-09-03 | Nippon Soda Co., Ltd. | Quinoline compound, and agricultural and horticultural fungicide |
| AU2018353150B2 (en) | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| US20210213014A1 (en) | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| CN108484680B (zh) | 2018-01-31 | 2020-12-11 | 马鞍山南京大学高新技术研究院 | 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物 |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| US12453279B2 (en) | 2018-08-22 | 2025-10-21 | Universal Display Corporation | Organic electroluminescent materials and devices |
| CN109265457A (zh) | 2018-11-01 | 2019-01-25 | 中国药科大学 | 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法 |
| EP3966208A4 (en) | 2019-05-10 | 2024-01-03 | Antidote IP Holdings, LLC | COMPOUNDS AND METHODS FOR TREATING CANCER |
| CN110283171A (zh) | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用 |
| US11820783B2 (en) | 2019-09-06 | 2023-11-21 | Universal Display Corporation | Organic electroluminescent materials and devices |
| CN116322696A (zh) | 2020-05-04 | 2023-06-23 | 安进公司 | 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法 |
| KR20230005893A (ko) | 2020-05-04 | 2023-01-10 | 다케다 야쿠힌 고교 가부시키가이샤 | 내강 작용 n-(피페리딘-4-일)벤즈아미드 유도체 |
| BR112022022281A2 (pt) | 2020-05-04 | 2023-01-03 | Adama Makhteshim Ltd | Misturas e composições compreendendo 5-fluoro-4-imino-3-metil- 1-tosil-3,4-dihidropirimidin-2-ona e métodos de uso das mesmas |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| CN111454265B (zh) | 2020-05-07 | 2021-08-24 | 宁波卢米蓝新材料有限公司 | 一种稠杂环化合物及其制备方法和应用 |
| CN118633022A (zh) | 2022-01-11 | 2024-09-10 | 雷杰纳荣制药公司 | 骨髓细胞上表达的触发受体2(trem2)变体以及其在治疗阿尔茨海默病中的用途 |
-
2021
- 2021-05-03 TW TW110115924A patent/TW202208355A/zh unknown
- 2021-05-04 PH PH1/2022/552949A patent/PH12022552949A1/en unknown
- 2021-05-04 EP EP21800538.7A patent/EP4146222A4/en active Pending
- 2021-05-04 KR KR1020227038841A patent/KR20230019822A/ko active Pending
- 2021-05-04 MX MX2022013842A patent/MX2022013842A/es unknown
- 2021-05-04 IL IL297833A patent/IL297833A/en unknown
- 2021-05-04 JP JP2022567487A patent/JP7754846B2/ja active Active
- 2021-05-04 US US17/302,502 patent/US11608344B2/en active Active
- 2021-05-04 BR BR112022022341A patent/BR112022022341A2/pt unknown
- 2021-05-04 CU CU2022000064A patent/CU24735B1/es unknown
- 2021-05-04 AR ARP210101218A patent/AR122010A1/es unknown
- 2021-05-04 AU AU2021266805A patent/AU2021266805A1/en active Pending
- 2021-05-04 PE PE2022002567A patent/PE20230846A1/es unknown
- 2021-05-04 WO PCT/US2021/070507 patent/WO2021226629A1/en not_active Ceased
- 2021-05-04 CR CR20220560A patent/CR20220560A/es unknown
- 2021-05-04 CA CA3182105A patent/CA3182105A1/en active Pending
- 2021-05-04 CN CN202180047705.7A patent/CN115867284A/zh active Pending
-
2022
- 2022-11-02 JO JOJO/P/2022/0296A patent/JOP20220296A1/ar unknown
- 2022-11-03 CL CL2022003047A patent/CL2022003047A1/es unknown
- 2022-11-04 CO CONC2022/0015930A patent/CO2022015930A2/es unknown
- 2022-11-21 EC ECSENADI202289527A patent/ECSP22089527A/es unknown
- 2022-11-30 US US18/072,501 patent/US11884675B2/en active Active
- 2022-11-30 US US18/072,505 patent/US11912711B2/en active Active
-
2023
- 2023-09-21 US US18/472,147 patent/US12428425B2/en active Active
-
2025
- 2025-10-02 JP JP2025166168A patent/JP2026004465A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021226629A1 (en) | 2021-11-11 |
| US20240182477A1 (en) | 2024-06-06 |
| EP4146222A1 (en) | 2023-03-15 |
| CR20220560A (es) | 2023-08-18 |
| TW202208355A (zh) | 2022-03-01 |
| JP2023525035A (ja) | 2023-06-14 |
| JP2026004465A (ja) | 2026-01-14 |
| KR20230019822A (ko) | 2023-02-09 |
| US20230295170A1 (en) | 2023-09-21 |
| CU24735B1 (es) | 2025-02-07 |
| BR112022022341A2 (pt) | 2023-01-10 |
| US11912711B2 (en) | 2024-02-27 |
| CL2022003047A1 (es) | 2023-07-14 |
| EP4146222A4 (en) | 2024-10-09 |
| US11884675B2 (en) | 2024-01-30 |
| CO2022015930A2 (es) | 2023-01-26 |
| US12428425B2 (en) | 2025-09-30 |
| PH12022552949A1 (en) | 2024-02-12 |
| US20230002390A1 (en) | 2023-01-05 |
| CN115867284A (zh) | 2023-03-28 |
| US20230295169A1 (en) | 2023-09-21 |
| CA3182105A1 (en) | 2021-11-11 |
| MX2022013842A (es) | 2023-02-22 |
| IL297833A (en) | 2023-01-01 |
| AU2021266805A1 (en) | 2022-12-01 |
| CU20220064A7 (es) | 2023-06-13 |
| PE20230846A1 (es) | 2023-05-23 |
| JP7754846B2 (ja) | 2025-10-15 |
| ECSP22089527A (es) | 2023-02-28 |
| AR122010A1 (es) | 2022-08-03 |
| US11608344B2 (en) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220295A1 (ar) | مركبات غير متجانسة الحلقات كمستقبل حاث يتم التعبير عنه على مواد مساعدة للخلايا النقيية 2 وطرق استخدامها | |
| PH12022552949A1 (en) | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | |
| MX2023012901A (es) | Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso. | |
| CR20210007A (es) | Degradadores selectivos del receptor de estrógeno | |
| Campos Rosa et al. | Synthesis, molecular modeling, and pharmacological testing of bis-quinolinium cyclophanes: potent, non-peptidic blockers of the apamin-sensitive Ca2+-activated K+ channel | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| BR112020001825A2 (pt) | compostos e métodos para a degradação direcionada de receptor de androgênio | |
| CA2642211A1 (en) | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases | |
| CO6190511A2 (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| BRPI0409938A (pt) | derivados de azetidinacarboxamida e seu uso em terapia | |
| PT1716152E (pt) | Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. | |
| ITMI20041566A1 (it) | "trpv1 agonisti, formulazioni che li contengono e loro usi" | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| BRPI0807968A2 (pt) | Composições farmacêuticas compreendendo antagonistas do receptor nk1 e bloqueadores do canal de sódio | |
| JOP20250025A1 (ar) | صور بلورية وأملاح من ناهض مستقبل مسكاريني | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| EA200801001A1 (ru) | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| MX2009012383A (es) | Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. | |
| WO2024233847A3 (en) | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| PY19100637A (es) | Compuestos químicos |